Form 4: Arrowhead CFO Executes Planned Stock Sale

Arrowhead Pharmaceuticals CFO Daniel Joseph Apel sold 13,095 shares of common stock to satisfy tax obligations via a 10b5-1 plan.

Summary

• CFO Daniel Joseph Apel sold a total of 13,095 shares of Arrowhead Pharmaceuticals common stock on April 22, 2026.
• The sales were executed in three tranches at weighted average prices of $70.11, $70.45, and $71.92.
• The transactions were conducted pursuant to a pre-established Rule 10b5-1 trading plan.
• The primary purpose of the sale was to satisfy tax withholding obligations related to the vesting of equity awards.
• Following these transactions, the reporting person retains beneficial ownership of 162,905 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a routine, pre-planned transaction for tax purposes rather than a discretionary divestment.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating the transaction was not based on non-public information.
• The transaction was specifically identified as a mechanism to cover tax liabilities, a standard practice for corporate executives.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Future share price volatility could impact the value of the remaining 162,905 shares held by the CFO.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirmed the sales were made pursuant to a 10b5-1 trading plan to satisfy tax withholding obligations.

Industry Context

StockSavvy.ai notes that executive stock sales for tax purposes are routine corporate events and generally do not signal a change in management's outlook on the company's long-term prospects.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives to manage equity holdings while avoiding potential insider trading concerns.
• The sale of shares to cover tax withholding upon the vesting of restricted stock units is a standard practice among biotech and pharmaceutical executives.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and related to tax obligations.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Trading, Form 4, CFO, 10b5-1